Attovia Therapeutics, Inc.(ATTO)

Biotechnology · San Carlos, CA

$17.86-0.14 (-0.75%)

Delayed quote: Oct 6, 2026, 2:19 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:20:33.562Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:20:33.562Z.

Quote observation: 2026-10-06T18:19:48.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 768,515,800
Total debt · period ending 2026-06-30: 4,325,999
Cash · period ending 2026-06-30: 32,829,000
TTM operating income · period ending 2026-06-30: N/A

FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ATTO EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

ATTO Competitors' EV/EBIT Ratio

ATTO

Attovia Therapeutics, Inc.

Current

Market Cap

$768.52M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLAB

Mesa Laboratories, Inc.

vs ATTO

Market Cap

$760.87M

EV/EBIT Ratio

36.99x

TTM Avg

38.85x

3Y Avg

65.92x

5Y Avg

138.61x

LXRX

Lexicon Pharmaceuticals, Inc.

vs ATTO

Market Cap

$775.12M

EV/EBIT Ratio

N/A

TTM Avg

15.22x

3Y Avg

6.50x

5Y Avg

6.50x

APMD

Apnimed, Inc.

vs ATTO

Market Cap

$755.05M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SANA

Sana Biotechnology, Inc.

vs ATTO

Market Cap

$776.41M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VREX

Varex Imaging Corporation

vs ATTO

Market Cap

$778.02M

EV/EBIT Ratio

14.58x

TTM Avg

14.71x

3Y Avg

18.13x

5Y Avg

17.67x

DSGN

Design Therapeutics, Inc.

vs ATTO

Market Cap

$747.61M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GERN

Geron Corporation

vs ATTO

Market Cap

$782.66M

EV/EBIT Ratio

N/A

TTM Avg

957.13x

3Y Avg

957.13x

5Y Avg

957.13x

AHCO

AdaptHealth Corp.

vs ATTO

Market Cap

$785.48M

EV/EBIT Ratio

N/A

TTM Avg

13.71x

3Y Avg

14.97x

5Y Avg

19.98x

GYRE

Gyre Therapeutics, Inc.

vs ATTO

Market Cap

$792.69M

EV/EBIT Ratio

N/A

TTM Avg

103.45x

3Y Avg

72.64x

5Y Avg

72.64x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Attovia Therapeutics, Inc. (ATTO)	$768.52M	N/A	N/A	N/A	N/A
Mesa Laboratories, Inc. (MLAB)vs ›	$760.87M	36.99x	38.85x	65.92x	138.61x
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$775.12M	N/A	15.22x	6.50x	6.50x
Apnimed, Inc. (APMD)vs ›	$755.05M	N/A	N/A	N/A	N/A
Sana Biotechnology, Inc. (SANA)vs ›	$776.41M	N/A	N/A	N/A	N/A
Varex Imaging Corporation (VREX)vs ›	$778.02M	14.58x	14.71x	18.13x	17.67x
Design Therapeutics, Inc. (DSGN)vs ›	$747.61M	N/A	N/A	N/A	N/A
Geron Corporation (GERN)vs ›	$782.66M	N/A	957.13x	957.13x	957.13x
AdaptHealth Corp. (AHCO)vs ›	$785.48M	N/A	13.71x	14.97x	19.98x
Gyre Therapeutics, Inc. (GYRE)vs ›	$792.69M	N/A	103.45x	72.64x	72.64x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

ATTO EV/EBIT Ratio Metrics

ATTO Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics